Cargando…
Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization
Alzheimer’s disease (AD) is a neurodegenerative disorder associated with marked oxidative stress at the level of the brain. Recent studies indicate that increasing the antioxidant capacity could represent a very promising therapeutic strategy for AD treatment. Astaxanthin (AST), a powerful natural a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913486/ https://www.ncbi.nlm.nih.gov/pubmed/33546352 http://dx.doi.org/10.3390/nano11020391 |
_version_ | 1783656813137231872 |
---|---|
author | Santonocito, Debora Raciti, Giuseppina Campisi, Agata Sposito, Giovanni Panico, Annamaria Siciliano, Edy Angela Sarpietro, Maria Grazia Damiani, Elisabetta Puglia, Carmelo |
author_facet | Santonocito, Debora Raciti, Giuseppina Campisi, Agata Sposito, Giovanni Panico, Annamaria Siciliano, Edy Angela Sarpietro, Maria Grazia Damiani, Elisabetta Puglia, Carmelo |
author_sort | Santonocito, Debora |
collection | PubMed |
description | Alzheimer’s disease (AD) is a neurodegenerative disorder associated with marked oxidative stress at the level of the brain. Recent studies indicate that increasing the antioxidant capacity could represent a very promising therapeutic strategy for AD treatment. Astaxanthin (AST), a powerful natural antioxidant, could be a good candidate for AD treatment, although its use in clinical practice is compromised by its high instability. In order to overcome this limit, our attention focused on the development of innovative AST-loaded stealth lipid nanoparticles (AST-SSLNs) able to improve AST bioavailability in the brain. AST-SSLNs prepared by solvent-diffusion technique showed technological parameters suitable for parenteral administration (<200 nm). Formulated nanosystems were characterized by calorimetric studies, while their toxicological profile was evaluated by the MTT assay on the stem cell line OECs (Olfactory Ensheathing Cells). Furthemore, the protective effect of the nanocarriers was assessed by a long-term stability study and a UV stability assay confirming that the lipid shell of the nanocarriers was able to preserve AST concentration in the formulation. SSLNs were also capable of preserving AST’s antioxidant capacity as demonstrated in the oxygen radical absorbance capacity (ORAC) assay. In conclusion, these preliminary studies outline that SSLNs could be regarded as promising carriers for systemic administration of compounds such as AST aimed at AD treatment. |
format | Online Article Text |
id | pubmed-7913486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79134862021-02-28 Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization Santonocito, Debora Raciti, Giuseppina Campisi, Agata Sposito, Giovanni Panico, Annamaria Siciliano, Edy Angela Sarpietro, Maria Grazia Damiani, Elisabetta Puglia, Carmelo Nanomaterials (Basel) Article Alzheimer’s disease (AD) is a neurodegenerative disorder associated with marked oxidative stress at the level of the brain. Recent studies indicate that increasing the antioxidant capacity could represent a very promising therapeutic strategy for AD treatment. Astaxanthin (AST), a powerful natural antioxidant, could be a good candidate for AD treatment, although its use in clinical practice is compromised by its high instability. In order to overcome this limit, our attention focused on the development of innovative AST-loaded stealth lipid nanoparticles (AST-SSLNs) able to improve AST bioavailability in the brain. AST-SSLNs prepared by solvent-diffusion technique showed technological parameters suitable for parenteral administration (<200 nm). Formulated nanosystems were characterized by calorimetric studies, while their toxicological profile was evaluated by the MTT assay on the stem cell line OECs (Olfactory Ensheathing Cells). Furthemore, the protective effect of the nanocarriers was assessed by a long-term stability study and a UV stability assay confirming that the lipid shell of the nanocarriers was able to preserve AST concentration in the formulation. SSLNs were also capable of preserving AST’s antioxidant capacity as demonstrated in the oxygen radical absorbance capacity (ORAC) assay. In conclusion, these preliminary studies outline that SSLNs could be regarded as promising carriers for systemic administration of compounds such as AST aimed at AD treatment. MDPI 2021-02-03 /pmc/articles/PMC7913486/ /pubmed/33546352 http://dx.doi.org/10.3390/nano11020391 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Santonocito, Debora Raciti, Giuseppina Campisi, Agata Sposito, Giovanni Panico, Annamaria Siciliano, Edy Angela Sarpietro, Maria Grazia Damiani, Elisabetta Puglia, Carmelo Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization |
title | Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization |
title_full | Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization |
title_fullStr | Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization |
title_full_unstemmed | Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization |
title_short | Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization |
title_sort | astaxanthin-loaded stealth lipid nanoparticles (ast-ssln) as potential carriers for the treatment of alzheimer’s disease: formulation development and optimization |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913486/ https://www.ncbi.nlm.nih.gov/pubmed/33546352 http://dx.doi.org/10.3390/nano11020391 |
work_keys_str_mv | AT santonocitodebora astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization AT racitigiuseppina astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization AT campisiagata astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization AT spositogiovanni astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization AT panicoannamaria astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization AT sicilianoedyangela astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization AT sarpietromariagrazia astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization AT damianielisabetta astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization AT pugliacarmelo astaxanthinloadedstealthlipidnanoparticlesastsslnaspotentialcarriersforthetreatmentofalzheimersdiseaseformulationdevelopmentandoptimization |